The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Seed Amplification Assay Program, 2022Development of a Reliable Diagnostic Test for Parkinson’s Disease Using Patient Blood Samples
Study Rationale: Although diagnosis of Parkinson’s disease (PD) is crucial for the success of treatment, especially in the early stages, there are still no biomarkers available for use as a reliable...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease
Study Rationale: A hallmark characteristic of Parkinson’s disease (PD) is the accumulation of alpha-synuclein, a small lipid-binding protein involved in transporting lipids and proteins throughout the...
-
Therapeutic Pipeline Program, 2021Identifying Small Molecule Binders of the LRRK2 WD Domain
Study Rationale:
Individuals with genetic variations or mutations in a gene called LRRK2 are at increased risk of developing Parkinson’s disease (PD). Because these alterations enhance the activity of... -
Therapeutic Pipeline Program, 2021Assessing the Potential of Low-Dose Carbon Monoxide Therapy in Parkinson’s Disease
Study Rationale:
Although carbon monoxide (CO) is commonly considered harmful, a growing body of research suggests that low doses of CO can stimulate physiologic processes that may protect against... -
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Overcoming Underrepresentation to Improve Generalizability in Fox Insight
Study Rationale:
Fox Insight is an online clinical study that surveys over 25,000 people with Parkinson disease (PD) about their overall health, symptoms and well-being. Unfortunately, certain groups...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.